EP1395224A2 - Forme posologique orale inviolable - Google Patents

Forme posologique orale inviolable

Info

Publication number
EP1395224A2
EP1395224A2 EP02753331A EP02753331A EP1395224A2 EP 1395224 A2 EP1395224 A2 EP 1395224A2 EP 02753331 A EP02753331 A EP 02753331A EP 02753331 A EP02753331 A EP 02753331A EP 1395224 A2 EP1395224 A2 EP 1395224A2
Authority
EP
European Patent Office
Prior art keywords
dosage form
oral dosage
cleavage
insoluble component
susceptible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02753331A
Other languages
German (de)
English (en)
Other versions
EP1395224A4 (fr
Inventor
Curtis Wright, Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of EP1395224A2 publication Critical patent/EP1395224A2/fr
Publication of EP1395224A4 publication Critical patent/EP1395224A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells

Definitions

  • the present invention relates to a dosage form including substances adhered to the therapeutic agent which are soluble in the gastrointestinal tract.
  • the dosage forms of the invention are either encapsulated with or modified by acid labile substances or linkages that are particularly susceptible to gastric enzymes.
  • the therapeutic agent in the dosage form is unavailable unless taken as directed.
  • tablets are unit dose forms that offer the greatest uniformity of content, in a light and compact package.
  • tablets are relatively simple and inexpensive to produce, package, and ship. Tablets also offer the greatest ease of swallowing, especially when coated, they easily lend themselves to certain special-release profile products, such as enteric or delayed-release products, and they have the best combined properties of chemical, mechanical, and microbiological stability of all oral dosage forms.
  • enteric or delayed-release products are currently available ' in tablet form.
  • oral dosage forms are not free from abuse, especially certain analgesics that are capable of rapid pain relief with a simultaneous euphoric effect. Enteric coatings have been used to modify drug release in oral dosage forms.
  • Enteric coatings are designed to remain intact in the stomach, but will dissolve and release the contents of the dosage form in the small intestine.
  • the coatings are generally used to delay the release of drugs that are inactivated by the stomach contents or that may irritate the gastric mucosa, thereby causing nausea or bleeding.
  • the action of enteric coatings results from a difference in composition of the gastric and intestinal environments with respect to pH and the presence of endogenous enzymes.
  • Most enteric coatings are formulated to remain intact in the low pH of the stomach, but readily dissolve when the pH rises to about 4-5.
  • the most effective enteric polymers are poly acids having a pKa of 3-5. See Remington: The Science and Practice of Pharmacy, 19 th Ed.. Ed. Alfonso R. Gennaro, et al., Philadelphia College of Pharmacy and Science (1995), p. 1653 et seq.
  • enteric coatings have not been used to deter abuse and provide a tamper resistant dosage form.
  • U.S. Patent No. 5,840,332 to Lerner et al. provides a gastrointestinal delivery system that includes a drug in combination with a core material that is surrounded by a water insoluble coating.
  • the dosage form absorbs liquid, thereby forming channels interconnecting the drug- containing core with the outside of the delivery device. These channels therefore, allow the release of the drug from the core into the gastrointestinal tract.
  • U.S. Patent No. 5,849,327 to Hopkins et al. describes a dosage form that permits delivery of a therapeutic agent to the lower gastrointestinal tract.
  • the dosage form is oral ingested and contains a plurality of porous microscopic beads, wherein the therapeutic agent is contained within the pores and the pores are plugged with a polysaccharide that is chemically degradable by colonic-specific bacteria.
  • the dosage form also contains an enteric coating that insures that the dosage form remains intact until it reaches the lower gastrointestinal system.
  • the prior art dosage forms do not address the unique problems posed by therapeutic agents prone to abuse, such that when taken as directed, the therapeutic agent is delivered properly, but when abused, the normal delivery mechanism is circumvented or interrupted to prevent abuse by an unintended user.
  • the present invention addresses these problems by encapsulating or covalently modifying the therapeutic agent with an insoluble component that is cleaved by enzymes endogenous to the gastrointestinal tract, but which is not susceptible to cleavage by intestinal saccharidases.
  • the present invention overcomes the problems posed by the abuse of oral dosage forms by providing the therapeutic agent in a form that renders the therapeutic agent insoluble outside the gastrointestinal tract. Therefore, the oral dosage form of the present invention does not release the therapeutic agent unless and until the dosage form is properly ingested.
  • the present invention provides an oral dosage form consisting of a therapeutic agent and an insoluble component adhered to the therapeutic agent, i.e., encapsulating or linked to the therapeutic agent, such that the dosage form is insoluble outside of the gastrointestinal tract.
  • the insoluble component is covalently linked to the therapeutic agent, and optionally, the covalent linkage is a chemical bond that is susceptible to cleavage by colonic bacteria, but not susceptible to cleavage by intestinal saccharidases.
  • the present invention provides a dosage form in which an insoluble component encapsulates the therapeutic agent.
  • the insoluble component may be a protein that is susceptible to proteolytic digestion by enzymes endogenous to the gastrointestinal tract.
  • the protein is an immunoglobulin construct, e.g., a synthetic antibody.
  • the therapeutic agent is dispersed in a pellet, bead, or microparticle, and the pellet, bead or microparticle is encapsulated by the protein.
  • an insoluble gel is formed that prevents absorption of the therapeutic agent.
  • the dosage form of the present invention includes a high surface area suspension of particles, film, gel or other physical substrate that is insoluble and encapsulates or is linked to the active therapeutic agent and renders it insoluble outside of the gastrointestinal tract.
  • in vitro solubilization of the dosage form is difficult and/or time consuming because the dosage form must interact with the patient's gastrointestinal tract to release the therapeutic agent.
  • the delayed or controlled release profile of the dosage form prevents or limits the potential for abuse by improper use.
  • the dosage forms of the present invention are soluble in the gastrointestinal tract, i.e., in the stomach and intestine, and generally insoluble elsewhere due to encapsulation of or attachment to a therapeutic agent a substance which is acid labile or which contains an acid labile linkage. Once exposed to the acidic environment of the gastrointestinal tract (pH less than 4), the substance is released from the therapeutic, i.e., either the acid labile linkage is cleared or the acid labile substance is degraded and the therapeutic agent is revealed.
  • the gastrointestinal tract contains certain enteric peptidases that are not generally present elsewhere in the human body because they are optimally active only in an acidic environment and the dosage forms of the invention include substances (encapsulating or linked to the therapeutic) that are susceptible to enteric peptidases but which are not degraded by intestinal saccharides.
  • enteric peptidases such as pepsin
  • acid proteases such as pepsin
  • Pepsin contains two active site aspartate residues and one of which must be ionized for the enzyme to be active.
  • Two other digestive enzymes are trypsin and elastase.
  • the substances used to coat the therapeutic of the invention are degraded by or contain linkages that are cleared by pepsin, trypsin, or elastase.
  • the dosage form consists of a therapeutic agent and an insoluble component adhered to the therapeutic agent, such that the dosage form is insoluble outside of the gastrointestinal tract.
  • the insoluble component is covalently linked to the therapeutic agent, and more preferably, the covalent linkage is a chemical bond that is susceptible to cleavage by colonic bacteria, but not susceptible to cleavage by intestinal saccharidases.
  • the linkage is a an acid labile ester or amide linkage, a carbohydrate linkage, or a sulfonate or glucuronide.
  • the dosage form contains an insoluble component that encapsulates the therapeutic agent which is acid labile.
  • the insoluble component may be a protein that is susceptible to proteolytic digestion by enzymes endogenous to the gastrointestinal tract.
  • the protein is an immunoglobulin construct, e.g., a synthetic antibody.
  • the therapeutic agent is dispersed in a pellet, bead, or microparticle, and the pellet, bead or microparticle is acid labile.
  • the dosage form may be formulated for virtually any medicament, in a preferred embodiment, the therapeutic agent are fentanyl, buprenorphine, etorphine and related opioids, or any combinations thereof.
  • the present invention may be formulated into a pharmaceutical composition.
  • the pharmaceutical composition also may include additives, such as a pharmaceutically acceptable carrier, a flavorant, a sweetener, a preservative, a dye, a binder, a suspending agent, a dispersing agent, a colorant, a disintegrant, an excipient, a diluent, a lubricant, a plasticizer, an edible oil or any combination of any of the foregoing.
  • Suitable pharmaceutically acceptable carriers include, but are not limited to, ethanol; water; glycerol; aloe vera gel; allantoin; glycerin; vitamin A and E oils; mineral oil; PPG2 myristyl propionate; vegetable oils and solketal.
  • Suitable binders include, but are not limited to, starch; gelatin; natural sugars, such as glucose, sucrose and lactose; corn sweeteners; natural and synthetic gums, such as acacia, tragacanth, vegetable gum, and sodium alginate; carboxymethylcellulose; polyethylene glycol; waxes; and the like.
  • Suitable disintegrators include, but are not limited to, starch such as corn starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • Suitable lubricants include, but are not limited to, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • a suitable suspending agent is, but is not limited to, bentoite.
  • Suitable dispersing and suspending agents include, but are not limited to, synthetic and natural gums, such as vegetable gum, tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone and gelatin.
  • Suitable edible oils include, but are not limited to, cottonseed oil, sesame oil, coconut oil and peanut oil.
  • a suitable pharmaceutical diluent is, but is not limited to, water. Examples of additional additives include, but are not limited to, sorbitol; talc; stearic acid; and dicalcium phosphate.
  • the pharmaceutical compositions may be formulated as solid unit dosage forms, such as tablets, pills, and capsules.
  • Unit dosage forms may be used for oral, sublingual, or buccal administration.
  • Solid unit dosage forms may be prepared by mixing the compounds with a pharmaceutically acceptable carrier and any other desired additives as described above. The mixture is typically mixed until a homogeneous mixture of the compounds and the carrier and any other desired additives is formed, i.e., until the compounds are dispersed evenly throughout the composition.
  • Tablets or pills can be coated or otherwise compounded to form a unit dosage form that has delayed and/or prolonged action, such as time release and sustained release unit dosage forms.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • the two components also may be separated by different layers that produce selective delivery of the agonist and the antagonist.
  • the selective delivery is produced by differential solubilities of the layers in acid media or basic media.
  • the coatings surrounding the compound to be delivered are dissolved in an ordered manner. The selective delivery allows for one compound to be released in a time and location dependent manner when compared to another compound present in the same formulation.
  • the tablet or pill can contain a polymer that controls the release of one component in the gastrointestinal tract and allows the second component to be release latter in the tract.
  • Biodegradable polymers for controlling the release of the compound include, but are not limited to, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydro-pyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • the pharmaceutical composition or unit dosage forms of the present invention may be administered by a variety of routes such as oral, buccal, and sublingual.
  • the pharmaceutical compositions or unit dosage forms of the present invention may be administered to an animal, preferably a human being.
  • the daily dosage of the compounds may vary according to a variety of factors such as underlying disease states, the individual's condition, weight, sex and age and the mode of administration.
  • the pharmaceutical compositions can be provided in the form of scored or unscored solid unit dosage forms containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, or 50.0 milligrams of the agonist and/or antagonist for the symptomatic adjustment of the dosage to the patient to be treated.
  • the dosage regimen utilizing the formulation of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the absorption, distribution, metabolism, and excretion of a drug.
  • the pharmaceutical composition or unit dosage form may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • co-administration or sequential administration of other active agents may be desirable.
  • the active agents can be administered concurrently, or they each can be administered at separately staggered times.
  • the dosage amount may be adjusted when combined with other active agents as described above to achieve desired effects.
  • unit dosage forms of these various active agents may be independently optimized and combined to achieve a synergistic result wherein the pathology is reduced more than it would be if either active agent were used alone.
  • the formulation also may be administered as an additive to the feed by simply mixing the formulation with the feedstuff or by applying the formulation to the surface of animal feed.
  • the formulation may be mixed with a carrier and the resulting composition may then either be mixed with the feed or fed directly to the animal.
  • Suitable carriers include, but are not limited to, corn meal, citrus meal, fermentation residues, soya grits, dried grains, and the like.
  • the formulation may be intimately mixed with the carrier by, e.g., grinding, stirring, milling, or tumbling.
  • the amount of therapeutic agent present in the formulation is a therapeutic effective amount, i.e., that amount needed to produce a health benefit in the patient to which it is administered. Any method known to one of ordinary skill in the art may be used to prepare the formulations of the invention. In a specific embodiment, melt extrusion granulation or melt extrusion method are used to produce the dosage forms of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une forme posologique orale comprenant un médicament et un composant insoluble adhérant au médicament ou encapsulant celui-ci, susceptible au clivage par des bactéries du côlon et résistant au clivage grâce aux saccharidases intestinales.
EP02753331A 2001-05-22 2002-05-22 Forme posologique orale inviolable Ceased EP1395224A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29260301P 2001-05-22 2001-05-22
US292603P 2001-05-22
PCT/US2002/016269 WO2002094173A2 (fr) 2001-05-22 2002-05-22 Forme posologique orale inviolable

Publications (2)

Publication Number Publication Date
EP1395224A2 true EP1395224A2 (fr) 2004-03-10
EP1395224A4 EP1395224A4 (fr) 2005-10-26

Family

ID=23125385

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02753331A Ceased EP1395224A4 (fr) 2001-05-22 2002-05-22 Forme posologique orale inviolable

Country Status (3)

Country Link
EP (1) EP1395224A4 (fr)
AU (1) AU2002313628A1 (fr)
WO (1) WO2002094173A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
CN1747737A (zh) * 2003-01-13 2006-03-15 新河药品股份有限公司 糖偶联物防止管制药物的滥用
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
UA82880C2 (en) 2003-04-30 2008-05-26 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087933C (zh) * 1993-06-30 2002-07-24 藤泽药品工业株式会社 装胶囊的药物
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO02094173A2 *
SUZAWA T ET AL: "Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation." BIOORGANIC & MEDICINAL CHEMISTRY. AUG 2000, vol. 8, no. 8, August 2000 (2000-08), pages 2175-2184, XP002342901 ISSN: 0968-0896 *

Also Published As

Publication number Publication date
EP1395224A4 (fr) 2005-10-26
WO2002094173A2 (fr) 2002-11-28
WO2002094173A3 (fr) 2003-02-20
AU2002313628A1 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
US7125561B2 (en) Compartmentalized dosage form
JP4088420B2 (ja) 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤
CN100353933C (zh) 快速溶化口服药物制剂
WO1997047285A1 (fr) Systeme a caracteristiques de retention renforcees pour l'administration controlee par voie orale de medicaments a retention gastrique
JP2001500879A (ja) 可溶性に乏しい薬物および不溶性の物質の制御放出のための胃滞留性経口薬物投薬形態
CN102105136A (zh) 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
CN101626757A (zh) 具有高比例活性剂的快速溶解/崩解的膜剂
WO2008094877A2 (fr) Compositions pour l'administration orale de produits pharmaceutiques
AU729437B2 (en) Cefadroxil monohydrate tablet formulation
JP2001527023A (ja) 胃で保持するのに適合した長期放出性活性剤剤形
US20130071476A1 (en) Rapid Melt Controlled Release Taste-Masked Compositions
CN102596252A (zh) 用于对乙酰氨基酚的立即和延长释放的胃滞留药物组合物
RU2327446C2 (ru) Состав с высвобождением в толстом кишечнике
KR20010042536A (ko) 정제의 제조방법 및 정제
US5468503A (en) Oral pharmaceutical preparation released at infragastrointestinal tract
US20020106408A1 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
EP2098225B1 (fr) Système de masquage de goût pour médicaments non plastifiés
WO2002094173A2 (fr) Forme posologique orale inviolable
US4863741A (en) Tablet composition for drug combinations
CZ296459B6 (cs) Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20040156844A1 (en) Tamper resistant oral dosage form
EP1000614A1 (fr) Composition contenant du sucralfate et procede de production
CA1266235A (fr) Combinaisons de medicaments en comprimes
EA012296B1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая не растворимый в кислотах полимер и биоадгезивный полимер
Tyagi et al. Formulation and evaluation of immediate release tablet of metformin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050912

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 47/48 B

Ipc: 7A 61J 1/00 A

17Q First examination report despatched

Effective date: 20061221

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EURO-CELTIQUE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090921